Evidence map›Paper›PMID 39134785›Full record

ArticleUrologie (Heidelberg, Germany)2024

[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024].

Maurice Stephan Michel, Jürgen E Gschwend, Bernd Wullich, Susanne Krege, Christian Bolenz, Axel S Merseburger, Laura-Maria Krabbe, Daniela Schultz-Lampel, Frank König, Axel Haferkamp and 1 more

Abstract readEnglish AbstractConsensus Statement
PubMed Publisher
In one paragraph

Article in Urologie (Heidelberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maurice Stephan MichelDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland. Maurice-Stephan.Michel@medma.uni-heidelberg.de.
Jürgen E GschwendDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Bernd WullichDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Susanne KregeDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Christian BolenzDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Axel S MerseburgerDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Laura-Maria KrabbeDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Daniela Schultz-LampelDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Frank KönigDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Axel HaferkampDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.
Boris HadaschikDeutsche Gesellschaft für Urologie, Geschäftsstelle Berlin, Martin-Buber-Straße 10, 14163, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveDespite the proven effectiveness of organized PSA-based screening in reducing prostate cancer-related mortality, there is currently no program in Germany covered by statutory health insurance. In accordance with the EU Council Decision (2022/0290(NLE)), the German Society of Urology (DGU) has developed a concept for risk-adapted prostate cancer early detection. MATERIALS AND

methodsBased on a literature review of current screening studies, an algorithm for PSA-based prostate cancer early detection was developed.

resultsRisk-adapted prostate cancer screening involves PSA testing in the age group of 45-70 years, followed by PSA-based individual risk stratification and stepwise expansion of diagnostics through magnetic resonance imaging (MRI) to biopsy. While initially up to 2.6 million men will undergo PSA testing, a reduction in these initial examinations to fewer than 200,000 men per year will occur from year four onwards.

conclusionsThe presented algorithm provides clear recommendations for risk-adapted PSA-based early detection for prostate cancer for urologists and patients. The goal is to improve diagnosis of clinically significant prostate cancer, while reducing overdiagnosis and overtreatment.

Indexed as

AlgorithmsEarly Detection of CancerProstate-Specific AntigenProstatic NeoplasmsUrologyAgedGermanyHumansMaleMiddle AgedReview Literature as TopicRisk AssessmentSocieties, MedicalProstate-Specific AntigenEarly detection of cancermpMRTProstate cancerProstate-specific antigenScreening

Identifiers

PMID39134785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.